Industry Daily Summary
Industry Daily Summary: What Happened on November 11, 2026
argenx agrees to buy Unnatural Products for up to $1.15 billion
CVS plans to separate its pharmacy and health businesses. Oura is planning a $625 million acquisition of Counsel Health.
Today in brief
argenx will pay $550 million upfront for Unnatural Products, with up to $595 million more tied to milestones.1 CVS plans to create two publicly traded companies, splitting its retail pharmacy business from its health care businesses.2 Oura is planning a $625 million deal for Counsel Health as wearable companies broaden their health care offerings.3
argenx adds a peptide discovery platform in a deal worth up to $1.15 billion
argenx agreed to acquire Unnatural Products, whose platform combines machine-learning-assisted compound design with large-scale synthesis and screening.14 The deal includes $550 million upfront and up to $595 million in development and regulatory milestone payments.1
The acquisition would give argenx full ownership of a company in which it previously held a minority stake.1 The companies expect to close by year-end, subject to customary conditions, and plan to keep Unnatural Products’ team at its Santa Cruz site.1
The companies began working together in July 2025 to discover oral or long-acting treatments for immune-mediated diseases.1
CVS plans to separate its retail pharmacy from its health businesses
After a strategic review, CVS plans to form two publicly traded companies, with the separation expected in the first half of 2028, subject to approvals and other conditions.2 A health care solutions company would retain Aetna, Caremark, CVS Specialty, Oak Street Health, and Signify Health. The other company would operate retail pharmacies and related services.2
The plan keeps the insurer and pharmacy benefit manager together while splitting off retail dispensing.2 CVS said the separation could give each business more strategic focus and let the pharmacy company pursue broader commercial partnerships.2
CVS expanded across insurance, pharmacy benefits, and retail through acquisitions including Caremark in 2007 and Aetna in 2018.2
Oura plans to buy Counsel Health for $625 million
Oura is planning to acquire Counsel Health in a deal valued at $625 million.3 The planned acquisition comes as wearable companies broaden their health care offerings.3
Also worth knowing
-
P
AstraZeneca acquired Omniose, bringing its bacterial vaccine platform into the company’s infectious disease unit after a research collaboration that began in 2024.56
-
ProBio granted AbTis exclusive worldwide rights to a discovery-stage oncology antibody. AbTis plans to develop it as an antibody-drug conjugate using its site-specific conjugation technology.78
Also published
- Cut the Noise. Build Conviction: Turning Competitive Insights into Strategy and Implementation Fierce Pharma
- Patients not just at the table, but creating their own: In conversation with Donna Cryer pharmaphorum
- Executive Conversations: When Should Trade Teams Join Launch Planning? Pharmaceutical Commerce
- Longevity sector ambitions outpace regulatory and investment frameworks Pharmaceutical Technology
- Austria builds life sciences momentum European Biotechnology
- The PM Awards aren’t just for agencies. They’re for the people who make great work happen pharmaphorum
- OCT New England 2026: the next phase in China’s rise Clinical Trials Arena
- Weekly Tech+Bio #90: AI Momentum Moves Into Clinical Trials — Companies to Watch in 2026 Weekly Tech+Bio
- Executive Conversations: Why Trade Strategy Has to Start Before Launch Pharmaceutical Commerce
- AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform BioPharm International
- AstraZeneca Acquires Omniose, Adding Bioconjugation Platform to Vaccine Pipeline Pharmaceutical Executive